New York, New York--(Newsfile Corp. - June 11, 2021) - Levi & Korsinsky notifies investors that it has commenced an investigation of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) concerning possible violations of federal securities laws.
To view an enhanced version of this graphic, please visit:
On May 26, 2021, Ocugen announced its plan to submit an Emergency Use Authorization ("EUA") application for COVAXIN, a COVID-19 vaccine, to the U.S. Food & Drug Administration in June 2021.
On June 10, 2021, the Company said it would no longer pursue a EUA for Covaxin and would instead aim to file for a full U.S. approval of the shot.
On this news, the stock price plummeted and closed today at $6.69 per share, representing a 25.17% drop from yesterday's closing price of $9.31 per share. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/87327